Serious Infections are Not Increased in HIV Patients Treated with TNF Inhibitors
Infections are a concern for many when using tumor necrosis factor-α inhibitor (TNFi) therapy to treat inflammatory disorders. Even moreso in those at higher risk.
News
Severe, Refractory Psoriasis in HIV-Positive Patients: Are TNF Inhibitors a Solution?
Psoriasis and psoriatic arthritis are more prevalent, often more severe, and sometimes refractory to conventional treatments in HIV-positive patients, but clinicians are understandably concerned about moving on to immunosuppressive anti-tumor necrosis factor (TNF) agents when other treatments fai
Dinosaur Arthritis
The recent edition of Science has an interesting article on the cause of death in a dinosaur - septic arthritis.
Palentologists have unearthed a 70 million year old duck-billed dinosaur near New Jersey and found that the arm bones were not quite right.
RAPID3: An Effective Assessment Tool in Spondyloarthritis
Serial biomarker or clinical metric assessments are ubiquitous and commonly used to assess patients with rheumatoid arthritis (HAQ, CDAI, RAPID3), lupus (C3, C4, dsDNA) and gout (uric acid). But numerous disorders are either harder to assess or have tools or metrics that that are not commonly used.
MRI Findings Match Patients' Experience With RA
Patient-reported outcomes in rheumatoid arthritis (RA) correlate independently with measures of inflammation and structural damage on MRI scans, according to data from a longitudinal study.
Nerve Growth Factor Inhibitor Compounds Cartilage Loss in Osteoarthritis
Nerve growth factor (NGF) is a key modulator of pain perception, Inhibitors of NGF are being studied in several chronic pain conditions, including osteoarthritis (OA).
Problems with Red Flags in Diagnosing Low Back Pain
There is considerable heterogeneity in "red flags" amongst numerous low back pain (LBP) guidelines worldwide. A "red flags" denotes a finding, which if present, imparts a significantly high risk of underlying serious spinal pathology with considerable subsequent morbidity or mortality.
Biosimilars are Bioequivalent to Original TNF Inhibitors
Chingcuanco and coinvestigators have reported on their comparative analysis of biosimilars and their originator TNF inhibitors in the current issue of Annals of Internal Medicine. (Citation source: http://buff.ly/2arTd1q)
Canakinumab Yields Genetic and Disease Modifying Effects in TRAPS Patients
Tumor necrosis factor (TNF) receptor-associated periodic syndrome (TRAPS) is an autosomal-dominant autoinflammatory disease resulting from mutations of the TNF super family receptor 1A (TNFRSF1A) gene.
Meniscal Tears May Not Need Surgery
A study published in the British Medical Journal examines whether knee surgery or conservative medical management benefits those with degenerative meniscal tears. (Citation source http://buff.ly/2awVbKu)
RheumNow Week in Review - 29 July 2016
Dr Jack Cush reviews this week's highlights from RheumNow.com.
Long-Term Safety of Adalimumab Reviewed
Burmester and colleagues have published their review of the long-term outcomes and safety issues with the TNF inhibitor, adalimumab (ADA). The analysis included 15,132 patients exposed to adalimumab in global RA clinical trials.
